ALL-REMOTE COMPANY/WILMINGTON, Del. / Oct 08, 2025 / Business Wire / Phreesia, a leader in patient intake, outreach and activation, has been named to the 2025 Capterra Shortlists in the Appointment Reminder and Appointment Scheduling categories. The Capterra Shortlist is an independent assessment that evaluates user reviews and online search activity to identify a list of market leaders that offer the top products in various software categories.
"It’s exciting to be named to the 2025 Capterra Shortlists for Appointment Reminders and Scheduling,” said Phreesia CEO Chaim Indig. “Our digital tools help simplify scheduling for healthcare providers so they can boost engagement, reduce no-shows and accelerate patient care.”
These are the third and fourth Capterra Shortlists Phreesia has been named to so far in 2025. Earlier this year, Phreesia made the Capterra Shortlists for Patient Engagement and Medical Scheduling.
Phreesia has an overall rating of 4.3 out of 5 on Capterra, driven by direct feedback from clients. “The appointment confirmation has helped us cancel [would-be no-show] patients and decreased the number of phone calls we'd get to cancel or reschedule those patients,” one practice manager shared in a review on the Capterra site.
Capterra uses exclusive data and trusted reviews from verified software users to build its Capterra Shortlist reports, which present a comprehensive view of products’ recent popularity and ratings based on data from a defined timeframe.
For more information on Phreesia, visit www.phreesia.com.
About Phreesia
Phreesia is the trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 170 million patient visits in 2024—1 in 7 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit www.phreesia.com.
| Last Trade: | US$23.69 |
| Daily Change: | 0.28 1.20 |
| Daily Volume: | 124,625 |
| Market Cap: | US$1.420B |
September 04, 2025 September 04, 2025 September 02, 2025 May 28, 2025 March 12, 2025 | |

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load